What Is Glucagon-Like Peptide-1?

Glucagon-like peptide-1 is a hormone produced mainly by L-cells in the small intestine and colon. The body releases it in response to eating, particularly after meals containing carbohydrates and fats. Once in circulation, GLP-1 stimulates insulin secretion from the pancreas in a glucose-dependent way, suppresses glucagon release, slows gastric emptying, and signals satiety to the brain through the vagus nerve and hypothalamus.

GLP-1 has a very short half-life in the bloodstream, roughly one to two minutes, because the enzyme dipeptidyl peptidase-4 (DPP-4) breaks it down quickly. Pharmaceutical researchers spent decades engineering molecules that mimic GLP-1 but resist DPP-4 degradation. That work produced the GLP-1 receptor agonist drug class, which includes semaglutide and liraglutide. These are prescription medications approved by the FDA under specific brand names for specific indications. OTC supplements operate in an entirely different regulatory category.

Understanding this distinction matters because the supplement market has adopted GLP-1 language freely. A product labeled 'GLP-1 support' is not claiming to contain a GLP-1 receptor agonist. It is typically claiming that its ingredients may encourage the body's own L-cells to secrete more native GLP-1, or may slow GLP-1 breakdown. Whether those claims hold up to scrutiny depends on the ingredient and the quality of the evidence behind it.

How Do Supplements Claim to Affect GLP-1?

Most supplements in this category work through one of three proposed mechanisms. The first is stimulating endogenous GLP-1 secretion, meaning encouraging the gut's own L-cells to release more of the hormone. The second is slowing DPP-4 activity so that whatever GLP-1 is secreted stays active a little longer. The third is indirect: slowing gastric emptying or altering the gut microbiome in ways that may influence GLP-1 release over time. Manufacturers rarely specify which mechanism they're targeting, and many products combine ingredients that theoretically touch more than one pathway.

The ingredients most commonly cited in this context include berberine, dietary fibers (particularly beta-glucan, inulin, and psyllium), bitter melon extract, cinnamon extract, and certain short-chain fatty acid precursors. Each has a different evidence base, ranging from in-vitro cell studies to small randomized controlled trials in humans. The gap between those evidence tiers is significant, and conflating them is one of the most common problems in how these products are marketed.

It's also worth noting that native GLP-1 secretion is already stimulated by eating a meal, especially one containing protein and fiber. Some researchers argue that the measurable effects of certain supplements on GLP-1 levels may partly reflect the meal context in which they were tested, rather than a pharmacological action of the ingredient itself. Separating those effects cleanly requires careful study design, and not all published research has achieved that.

What Does the Evidence Show for Specific Ingredients?

Berberine is the ingredient with the most human trial data in this space. A 2012 study published in Metabolism (Yin et al., 12 participants with type 2 diabetes) found that berberine increased postprandial GLP-1 levels compared to placebo, with the proposed mechanism being DPP-4 inhibition. A 2019 review in Frontiers in Pharmacology summarized berberine's metabolic effects across multiple trials but noted that most studies were small, short in duration, and conducted in populations with existing metabolic dysfunction. Effects in healthy adults are less well characterized.

Beta-glucan, a soluble fiber found in oats and barley, has been studied for its effects on postprandial GLP-1 in several small human trials. A 2016 study in the European Journal of Nutrition (Mäkeläinen et al., 20 participants) found that a high-beta-glucan oat product increased GLP-1 responses compared to a low-fiber control. The effect sizes were modest and the study was short-term. Psyllium husk has shown similar patterns in a handful of trials, with researchers attributing the effect to viscosity slowing gastric emptying rather than direct L-cell stimulation.

Bitter melon and cinnamon extract appear frequently in supplement formulations, but their GLP-1 evidence is thinner. Most bitter melon research is in animal models or in-vitro systems. Cinnamon extract studies in humans have generally measured blood glucose and insulin rather than GLP-1 directly. Extrapolating from glucose effects to GLP-1 mechanism is a logical leap that the available data doesn't fully support. Consumers should treat ingredient-level claims carefully and look for whether the cited research actually measured GLP-1 in humans.

How Do These Supplements Compare to Approved GLP-1 Drugs?

This comparison is important to make plainly. FDA-approved GLP-1 receptor agonists like semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound, the latter of which also targets GIP receptors) are prescription drugs that have gone through large, multi-year randomized controlled trials. The STEP 1 trial of semaglutide, published in the New England Journal of Medicine in 2021, enrolled 1,961 adults and found a mean body weight reduction of about 14.9 percent over 68 weeks in the treatment group. These are pharmaceutical-grade molecules engineered to resist rapid breakdown and bind GLP-1 receptors with high affinity.

OTC supplements are not GLP-1 receptor agonists. They do not bind GLP-1 receptors. At best, some ingredients may nudge the body to secrete slightly more of its own short-lived GLP-1 after a meal. The magnitude of that effect, where it has been measured, is far smaller than what approved drugs produce. No supplement has been tested in a large RCT for weight or metabolic outcomes using GLP-1 as the mechanism, and no supplement carries FDA approval for any indication.

The regulatory distinction also matters for safety. Prescription GLP-1 drugs carry known side effect profiles documented across thousands of trial participants, and they're prescribed and monitored by clinicians. Supplements are regulated under the Dietary Supplement Health and Education Act of 1994, which does not require pre-market efficacy or safety testing. The FDA can act against a supplement after it's on the market if harm is demonstrated, but the bar for market entry is much lower than for drugs.

What Should Readers Take Away from the Current Evidence?

The research on GLP-1 supplements is early-stage and uneven. A handful of ingredients, particularly berberine and certain soluble fibers, have shown measurable effects on GLP-1 secretion in small human studies. That's a real signal worth watching. But small studies in specific populations, often people with metabolic disease, don't automatically translate to meaningful effects in the general population, and they don't establish that the GLP-1 effect is responsible for any clinical outcome the product might claim.

The supplement industry has moved faster than the research. Products are being sold with GLP-1 language that implies a mechanism of action the evidence doesn't fully support at the doses and combinations used in commercial formulations. Consumers who see 'GLP-1 support' on a label are often not aware that this phrase has no regulatory definition and no required evidentiary standard behind it.

Anyone curious about GLP-1 activity, whether through diet, lifestyle, or pharmaceutical options, should start with a conversation with a physician or registered dietitian. The science of GLP-1 is genuinely interesting and the pharmaceutical research is advancing quickly. The supplement evidence is worth following as it develops, but it's not at a stage where strong conclusions can be drawn about OTC products.

Frequently asked questions

Is berberine the same as a GLP-1 drug?

No. Berberine is a plant-derived alkaloid sold as a dietary supplement. It is not a GLP-1 receptor agonist and does not work the same way as prescription drugs like semaglutide or tirzepatide. Some small human studies suggest berberine may modestly increase postprandial GLP-1 secretion or inhibit the enzyme DPP-4, but the evidence base is limited in size and scope. Berberine has not been approved by the FDA for any medical indication, and comparing it to prescription GLP-1 drugs overstates what the current research supports.

Can eating more fiber raise GLP-1 levels?

Dietary fiber, particularly soluble fiber like beta-glucan and inulin, has been associated with increased postprandial GLP-1 responses in several small human studies. The proposed mechanism involves slowed gastric emptying and fermentation of fiber by gut bacteria into short-chain fatty acids, which can stimulate L-cells. However, these effects are modest and context-dependent. Fiber's broader metabolic benefits are well-documented, but framing high-fiber eating specifically as a GLP-1 strategy goes beyond what the current evidence firmly establishes.

Are GLP-1 supplements regulated by the FDA?

Dietary supplements marketed as GLP-1 supporters are regulated under the Dietary Supplement Health and Education Act of 1994, not as drugs. This means manufacturers do not need to prove efficacy or safety before selling them. The FDA can take action against a supplement if it's found to be unsafe or if its labeling makes illegal drug claims, but there is no pre-market approval process. This is fundamentally different from the approval pathway for prescription GLP-1 receptor agonist drugs, which require large clinical trials demonstrating safety and efficacy before they can be sold.

Sources

  1. Wilding et al., 2021, New England Journal of Medicine (STEP 1 semaglutide trial) Large RCT establishing semaglutide weight outcomes
  2. Yin et al., 2012, Metabolism (berberine and GLP-1) Small human trial on berberine and postprandial GLP-1
  3. Drucker, 2006, Cell Metabolism (GLP-1 biology review) Foundational review of GLP-1 physiology and pharmacology

Educational and informational content only. This is not medical advice, diagnosis, or treatment. The compounds discussed are research compounds that are not approved for human use outside specific prescribed contexts. Always consult a qualified, licensed clinician before making any health decision.